Organovo (ONVO) Announces Plans to Develop 3D Bioprinted Human Liver for Direct Transplant
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Organovo Holdings, Inc. (Nasdaq: ONVO) announced its plan to develop 3D bioprinted human liver tissue for direct transplantation to patients. The Company is announcing its program to develop this therapeutic tissue based on the achievement of strong results in preclinical studies in animal models showing engraftment, vascularization and sustained functionality of its bioprinted liver tissue, including stable detection of liver-specific proteins and metabolic enzymes. Organovo expects to pursue this opportunity with a formal preclinical development program.
For patients in need of a liver transplant, no robust alternatives exist today. Approximately 17,000 patients are on the U.S. liver transplant waiting list, and only 6,000 liver transplants are performed each year. Organovo plans to develop clinical solutions in two initial areas. First, acute-on-chronic liver failure (“ACLF”) is a recognized and distinct orphan disease entity encompassing an acute deterioration of liver function in patients with liver disease, which affects 150,000 patients annually in the United States. Second, pediatric metabolic liver diseases represent another orphan disease indication where a bioprinted liver tissue patch may show therapeutic benefits. The total addressable market opportunity for these initial indication areas exceeds $3 billion. Assuming development progresses according to its current plan, Organovo intends to submit an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) for its therapeutic liver tissue in three to five years. As appropriate, Organovo will pursue breakthrough therapy designation, clinical development outside the United States, and other opportunities to help accelerate time to market.
Keith Murphy, Organovo’s CEO, will be presenting bioprinted human liver as the first therapeutic tissue being advanced in the Company’s portfolio at the 2016 Cell & Gene Meeting on the Mesa in La Jolla, Ca. Mr. Murphy will speak today at 5 p.m. PT, and the presentation will be both webcast live and available for replay at http://www.meetingonthemesa.com/webcast/. The Company also expects to present more detailed preclinical results at upcoming scientific conferences.
“We’re excited to introduce an implantable bioprinted liver tissue as the first preclinical candidate in our therapeutic tissue portfolio, and see the early results as extremely promising,” said Keith Murphy, CEO, Organovo. “The scientific and commercial progress we have already made with ExViveTM Human Liver Tissue in drug toxicity testing has given us a firm foundation upon which to build a larger tissue for transplant. Advancing our first therapeutic tissue into preclinical development is an important milestone for Organovo, and it speaks to the power of our technology platform in addressing multiple applications, including preclinical safety, disease modeling and tissue replacement products for surgical implantation. We believe that 3D bioprinted tissues have an opportunity to provide options for patients who suffer from liver disorders.”
“Organovo’s approach is designed to overcome many of the challenges that cell therapies and conventional tissue engineering have struggled to address, including limited engraftment and significant migration of cells away from the liver,” said Eric Michael David, M.D., J.D., chief strategy officer and executive vice president of preclinical development, Organovo. “In our preclinical studies, we deliver a patch of functional tissue directly to the liver, which integrates well, remains on the liver and maintains functionality. We believe our tissues have the potential to extend the lives of patients on liver transplant lists, or those who do not qualify for transplants due to other factors.”
“Supply issues are a constant and growing challenge in transplant medicine and liver has the second highest transplant need among all organs,” said David A. Gerber, M.D., FACS, Professor of Surgery and Chief of Transplant Surgery, UNC School of Medicine. “New solutions in development, such as 3D bioprinted human tissues, have the potential to create tissues that could augment and extend organ function to give more time to those patients on transplant waiting lists. Moreover, we are continuing to push the boundaries and understand how to scale 3D bioprinting and tissue engineering to develop larger tissues.” Dr. Gerber serves as an advisor to Organovo on its liver therapeutic tissue preclinical development program.
Dr. John Geibel, Vice Chairman of Surgery, Director of Surgical Research, and Professor of Surgery and Cellular and Molecular Physiology at Yale University, added, “There are many conditions in areas such as liver, kidney, gastrointestinal, vascular, and lung disease where supplying a tissue patch may be curative, or bridge a patient a few more years before they need a transplant. The promise of 3D bioprinting human tissues to address these unmet needs is significant.” Organovo and the Methuselah Foundation support Organovo’s bioprinter for therapeutic research at Yale’s Department of Surgery.
The Company continues to conduct early research on other tissues for therapeutic use in direct surgical applications. Liver tissue, having ranked highly in an initial strategic assessment performed by Organovo considering technical feasibility, commercial opportunity, clinical, regulatory, and reimbursement factors, has moved forward most quickly as the Company’s first program for preclinical development. Preclinical ‘proof-of-concept’ is currently being pursued in additional areas, building on the breadth of Organovo’s leading bioprinting expertise.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Abbott (ABT) Files Complaint to Terminate Alere (ALR) Acquisition
- Gulfport Energy (GPOR) Announces $87M Acquisition of Monroe County Acreage
- Starbucks Coffee (SBUX) to Present Five-Year Growth Plan at Investor Conference
Create E-mail Alert Related CategoriesCorporate News, Hot Corp. News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!